Effect of sodium-glucose cotransporter 2 inhibitor on sarcopenia in elderly patients with type 2 diabetes

SONG Baona; LIN Ping; WANG Qin

doi:10.16766/j.cnki.issn.1674-4152.003039

Volume 21 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of General Practice > 2023 > 21(6): 1016-1020

SONG Baona, LIN Ping, WANG Qin. Effect of sodium-glucose cotransporter 2 inhibitor on sarcopenia in elderly patients with type 2 diabetes[J]. Chinese Journal of General Practice, 2023, 21(6): 1016-1020. doi: 10.16766/j.cnki.issn.1674-4152.003039

Citation:

SONG Baona, LIN Ping, WANG Qin. Effect of sodium-glucose cotransporter 2 inhibitor on sarcopenia in elderly patients with type 2 diabetes[J]. Chinese Journal of General Practice, 2023, 21(6): 1016-1020. doi: 10.16766/j.cnki.issn.1674-4152.003039

Citation:

PDF( 428 KB)

Effect of sodium-glucose cotransporter 2 inhibitor on sarcopenia in elderly patients with type 2 diabetes

doi: 10.16766/j.cnki.issn.1674-4152.003039

SONG Baona¹
, LIN Ping^{2
,
,}
, WANG Qin²

1.
The Fourth Clinical Medical College of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang 310053, China

Funds:

2018Z05

2019KY502

杭卫发[2021]21号

Received Date: 2022-02-10
Available Online: 2023-08-26

Abstract

Abstract

Type 2 diabetes is one of the common diseases of the elderly, and the incidence increases with the increase of age. Sarcopenia, or sarcopenia, is also a clinical syndrome associated with aging. Studies have shown that the incidence of sarcopenia in elderly patients with type 2 diabetes is increasing year by year. The pathogenesis of type 2 diabetes combined with sarcopenia mainly includes insulin resistance, chronic inflammation, oxidative stress, mitochondrial dysfunction, peripheral neuropathy and injury, and the use of hypoglycemic drugs. Many hypoglycemic drugs, such as biguanides, thiazolidinediketones, dipeptidyl peptiase-4 inhibitors (DPP-Ⅳ inhibitor), glucagon-like peptide-1 receptor agonist (GLP-1RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and other inhibitors have influence on the occurrence of sarcopenia. With the wide application of SGLT-2i in hypoglycemic treatment and cardiovascular disease treatment, the author found that it also has an important impact on sarcopenia. When used in elderly patients with type 2 diabetes, SGLT-2i can optimize the body structure and reduce fat without affecting muscle content or increasing the incidence of fracture. It can delay the occurrence of sarcopenia through the regulation and transcription of muscle and fat, improve oxidative phosphorylation and control inflammation. By influencing the central nervous system, the active food intake of patients can be increased and the risk of sarcopenia can be reduced from the level of malnutrition. Therefore, the application of SGLT-2i in elderly patients with type 2 diabetes can not only play a role in hypoglycemia and cardiovascular protection, but also has important significance in delaying the occurrence of sarcopenia. The application of SGLT-2i may bring new ideas and targets for the treatment of elderly patients with type 2 diabetes complicated with sarcopenia.
- Sodium and glucose co-transporter 2 inhibitor,
- Geriatric type 2 diabetes,
- Sarcopenia

FullText(HTML)

References(43)

References

[1]	国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2021年版)[J]. 中华老年医学杂志, 2021, 40(1): 1-33. doi: 10.3760/cma.j.issn.0254-9026.2021.01.001
[2]	LI Y, TENG D, SHI X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369: m997. DOI: 10.1136/bmj.m997.
[3]	AWAD S F, Al-MAWALI A, Al-LAWATI J A, et al. Forecasting the type 2 diabetes mellitus epidemic and the role of key risk factors in Oman up to 2050: mathematical modeling analyses[J]. J Diabetes Investig, 2021, 2(7): 1162-1174.
[4]	PAR A, HEGYI J P, VANCSA S, et al. Sarcopenia-2021: pathophysiology, diagnosis, therapy[J]. Orv Hetil, 2021, 162(1): 3-12. doi: 10.1556/650.2021.32015
[5]	刘娟, 丁清清, 周白瑜, 等. 中国老年人肌少症诊疗专家共识(2021)[J]. 中华老年医学杂志, 2021, 40(8): 943-952. doi: 10.3760/cma.j.issn.0254-9026.2021.08.001 LIU J, DING Q Q, ZHOU B Y, et al. Chinese expert consensus on diagnosis and treatment for elderly with sarcopenia(2021)[J]. Chinese Journal of Geriatrics, 2021, 40(8): 943-952. doi: 10.3760/cma.j.issn.0254-9026.2021.08.001
[6]	刘利利, 赵柯湘, 罗成, 等. 重庆市主城区中老年体检人群肌肉减少症患病率调查及危险因素分析[J]. 中华全科医学, 2019, 17(10): 1762-1767. doi: 10.16766/j.cnki.issn.1674-4152.001050 LIU L L, ZHAO K X, LUO C, et al. Prevalence and risk factors of sarcopenia in urban area of Chongqing[J]. Chinese Journal of General Practice, 2019, 17(10): 1762-1767. doi: 10.16766/j.cnki.issn.1674-4152.001050
[7]	FENG L, GAO Q, HU K, et al. Prevalence and risk factors of sarcopenia in patients with diabetes: a meta-analysis[J]. J Clin Endocrinol Metab, 2022, 107(5): 1470-1483. doi: 10.1210/clinem/dgab884
[8]	TAKAHASHI F, HASHIMOTO Y, KAJI A, et al. Sarcopenia is associated with a risk of mortality in people with type 2 diabetes mellitus[J]. Front Endocrinol (Lausanne), 2021, 12: 783363. DOI: 10.3389/fendo.2021.783363.
[9]	MU Z J, FU J L, SUN L N, et al. Associations between homocysteine, inflammatory cytokines and sarcopenia in Chinese older adults with type 2 diabetes[J]. BMC Geriatr, 2021, 21(1): 692. doi: 10.1186/s12877-021-02622-y
[10]	IZZO A, MASSIMINO E, RICCARDI G, et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors[J]. Nutrients, 2021, 13(1): 183. doi: 10.3390/nu13010183
[11]	MASSIMINO E, IZZO A, RICCARDI G, et al. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms[J]. Cells, 2021, 10(8): 1958. doi: 10.3390/cells10081958
[12]	CHEN F, XU S, WANG Y, et al. Risk factors for sarcopenia in the elderly with type 2 diabetes mellitus and the effect of metformin[J]. J Diabetes Res, 2020, 2020: 3950404. DOI: 10.1155/2020/3950404.
[13]	HASSAN F E, SAKR H I, MOHIE P M, et al. Pioglitazone improves skeletal muscle functions in reserpine-induced fibromyalgia rat model[J]. Ann Med, 2021, 53(1): 1032-1040.
[14]	TSURUTANI Y, NAKAI K, INOUE K, et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: a multicentre, randomized, prospective, open-label, active-controlled study[J]. Diabetes Obes Metab, 2018, 20(11): 2675-2679. doi: 10.1111/dom.13421
[15]	HONG Y, LEE J H, JEONG K W, et al. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy[J]. J Cachexia Sarcopenia Muscle, 2019, 10(4): 903-918. doi: 10.1002/jcsm.12434
[16]	GIUGLIANO D, LOGO M, SCAPPATICCIO L, et al. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes[J]. Cardiovasc Diabetol, 2021, 20(1): 17. doi: 10.1186/s12933-021-01213-w
[17]	TILINCA M C, TIUCA R A, TILEA I, et al. The SGLT-2 inhibitors in personalized therapy of diabetes mellitus patients[J]. J Pers Med, 2021, 11(12): 1249. doi: 10.3390/jpm11121249
[18]	SANO M, MEGURO S, KAWAI T, et al. Increased grip strength with sodium-glucose cotransporter 2[J]. J Diabetes, 2016, 8(5): 736-737. doi: 10.1111/1753-0407.12402
[19]	KURIYAN R. Body composition techniques[J]. Indian J Med Res, 2018, 148(5): 648-658. doi: 10.4103/ijmr.IJMR_1777_18
[20]	SARGEANT J A, HENSON J, KING J A, et al. A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans[J]. Endocrinol Metab (Seoul), 2019, 34(3): 247-262. doi: 10.3803/EnM.2019.34.3.247
[21]	XU H Q, LIU J M, ZHANG X, et al. Estimation of skeletal muscle mass by bioimpedance and differences among skeletal muscle mass indices for assessing sarcopenia[J]. Clin Nutr, 2021, 40(4): 2308-2318. doi: 10.1016/j.clnu.2020.10.021
[22]	WALOWSKI C O, BRAUN W, MAISCH M J, et al. Reference values for skeletal muscle mass-current concepts and methodological considerations[J]. Nutrients, 2020, 12(3): 755. doi: 10.3390/nu12030755
[23]	SASAKI T, SUGAWARA M, FUKUDA M. SGLT2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT Study with luseogliflozin[J]. J Diabetes Investig, 2019, 10(1): 108-117. doi: 10.1111/jdi.12851
[24]	KAMEI S, IWAMOTO M, KAMEYAMA M, et al. Effect of tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus[J]. J Diabetes Res, 2018, 2018: 6470137. DOI: 10.1155/2018/6470137.
[25]	MATSUBA I, TAKIHATA M, TAKAI M, et al. Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2021, 23(12): 2614-2622. doi: 10.1111/dom.14508
[26]	INOUE H, MORINO K, UGI S, et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial[J]. J Diabetes Investig, 2019, 10(4): 1012-1021. doi: 10.1111/jdi.12985
[27]	TOBITA H, SATO S, MIYAKE T, et al. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study[J]. Curr Ther Res Clin Exp, 2017, 87: 13-19. doi: 10.1016/j.curtheres.2017.07.002
[28]	SAKAMOTO M, GOTO Y, NAGAYAMA A, et al. Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes[J]. Diabetol Int, 2021, 13(1): 117-123.
[29]	BLAU J E, BAUMAN V, CONWAY E M, et al. Canagliflozin triggers the FGF23/1, 25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study[J]. JCI Insight, 2018, 3(8): e99123. DOI: 10.1172/jci.insight.99123.
[30]	BILEZIKIAN J P, WATTS N B, USISKIN K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin[J]. J Clin Endocrinol Metab, 2016, 101(1): 44-51. doi: 10.1210/jc.2015-1860
[31]	ZHUO M, HAWLEY C E, PAIK J M, et al. Association of sodium-glucose cotransporter-2 inhibitors with fracture risk in older adults with type 2 diabetes[J]. JAMA Netw Open, 2021, 4(10): e2130762. DOI: 10.1001/jamanetworkopen.2021.30762.
[32]	FRALICK M, KIM S C, SCHNEEWEISS S, et al. Fracture risk after initiation of use of Canagliflozin: a cohort study[J]. Ann Intern Med, 2019, 170(3): 155-163. doi: 10.7326/M18-0567
[33]	THRAILKILL K M, BUNN R C, UPPUGANTI S, et al. Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone[J]. Bone, 2020, 133: 115254. DOI: 10.1016/j.bone.2020.115254.
[34]	GERBER C, WANG X, DAVID V Q, et al. Long-term effects of SGLT-2 deletion on bone and mineral metabolism in mice[J]. JBMR Plus, 2021, 5(8): e10526. DOI: 10.1002/jbm4.10526.
[35]	BAMBA R, OKAMURA T, HASHIMOTO Y, et al. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice[J]. J Cachexia Sarcopenia Muscle, 2022, 13(1): 574-588. doi: 10.1002/jcsm.12814
[36]	YAMAKAGE H, TANAKA M, INOUE T, et al. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: a randomized, controlled trial[J]. J Diabetes Investig, 2020, 11(3): 653-661. doi: 10.1111/jdi.13179
[37]	JI L L, YEO D. Mitochondrial dysregulation and muscle disuse atrophy[J]. F1000 Res, 2019, 8: 1621. doi: 10.12688/f1000research.19139.1
[38]	OKAMURA T, HASHIMOTO Y, OSAKA T, et al. The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1[J]. J Clin Biochem Nutr, 2019, 65(1): 23-28. doi: 10.3164/jcbn.18-114
[39]	NAMBU H, TAKADA S, FUKUSHIMA A, et al. Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure[J]. European J Pharmacology, 2020, 866: 172810. DOI: 10.1016/j.ejphar.2019.172810.
[40]	XU L, NAGATA N, NAGASHIMADA M, et al. SGLT-2 inhibition by Empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice[J]. EBioMedicine, 2017, 20: 137-149. doi: 10.1016/j.ebiom.2017.05.028
[41]	PAN L, XIE W, FU X, et al. Inflammation and sarcopenia: a focus on circulating inflammatory cytokines[J]. Exp Gerontol, 2021, 154: 111544. doi: 10.1016/j.exger.2021.111544
[42]	NAZNIN F, SAKODA H, OKADA T, et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice[J]. European J Pharmacol, 2017, 794: 37-44. doi: 10.1016/j.ejphar.2016.11.028
[43]	TAKEDA K, ONO H, ISHIKAWA K, et al. Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats[J]. BMJ Open Diabetes Res Care, 2021, 9(1): e002104. DOI: 10.1136/bmjdrc-2020-002104.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (247) PDF downloads(11)

Effect of sodium-glucose cotransporter 2 inhibitor on sarcopenia in elderly patients with type 2 diabetes

doi: 10.16766/j.cnki.issn.1674-4152.003039

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of sodium-glucose cotransporter 2 inhibitor on sarcopenia in elderly patients with type 2 diabetes

doi: 10.16766/j.cnki.issn.1674-4152.003039

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content